MD Anderson 2020 Updates on Neoadjuvant Therapy in Melanoma: Are CPI Responses More Durable Than Targeted Therapy? How Can We Help IO Become a New SoC?

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

MD Anderson 2020 Updates on Neoadjuvant Therapy in Melanoma: Are CPI Responses More Durable Than Targeted Therapy? How Can We Help IO Become a New SoC?

By MD Anderson's The Art and Science of Managing the New Melanoma Landscape 2020 FEATURING Rodabe Amaria

0 views

November 19, 2020

Comments 0

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

Feat. G. Sonpavde

12:46

Stanford Medicine

FDA Approval of Lifileucel for Unresectable or Metastatic Melanoma: …

Feat. A. Betof Warner

24:14

Masterclasses in Dermatology

Advances in the Treatment of Melanoma

Feat. D. Fisher

11:05

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Highlights in Early Stage, 1L Metastatic, …

Feat. D. Johnson

35:23

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "My Personal Highlights in Melanoma"

Feat. S. Patel

25:29

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Insights in Melanoma"

Feat. O. Hamid

18:28

Vanderbilt University Medical Center (VUMC)

NCCN Guidelines Updates for the Management of Cutaneous Melanoma: Ne…

Feat. D. Johnson

22:27

2024 ASCO® Annual Meeting Insights Hub

Developmental Therapeutics Highlights From ASCO® 2024

Feat. G. Sonpavde

23:09

Total Health

Key Updates in Skin Melanoma

Feat. R. Seedor

10:39

University of Colorado Department of Medicine

Cardio-Oncology: Definitions and Scope

Feat. L. Kondapalli

08:41

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "NADINA Trial - Neoadjuvant Nivo + Ipi in …

Feat. C. Blank

09:54

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "RELATIVITY-047 Trial 3-Year OS and MSS Ou…

Feat. H. Tawbi

03:55

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "COMBI-AD Study - Dabrafenib + Trametinib …

Feat. A. Hauschild

06:39

Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Final Analysis of Distant Metastasis-Free…

Feat. J. Luke

17:39

Melanoma Bridge 2023

Major Emerging Paradigm Shifts That Will Change Melanoma Management …

Feat. A. Eggermont

28:32

West Virginia State Rheumatology Society

Checkpoint Inhibitors, Arthritis and Other Autoimmune Triggers

Feat. J. Bustamante

25:44

Scripps Health

Melanoma in the Molecular Age - Part 1: New Tools for Diagnosis, Pro…

Feat. G. Hosler

24:27

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Highlights in Melanoma - Neoadjuvant and A…

Feat. Z. Eroglu

17:07

MSKCC 2nd Annual Symposium on Advanced Therapeutics for Brain Metastasis

Melanoma Brain Metastases: Successes, Failures, and Future Opportuni…

Feat. M. Postow

11:27

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Curing Stage IV Melanoma - Where Have We B…

Feat. P. Corrie

Login

Login

Join VuMedi

MD Anderson 2020 Updates on Neoadjuvant Therapy in Melanoma: Are CPI Responses More Durable Than Targeted Therapy? How Can We Help IO Become a New SoC?

Recommended